Molecular Neurodegeneration 2013-01-01

Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.

Miguel M Carvalho, Filipa L Campos, Bárbara Coimbra, José M Pêgo, Carla Rodrigues, Rui Lima, Ana J Rodrigues, Nuno Sousa, António J Salgado

Index: Molecular Neurodegeneration 8 , 14, (2013)

Full Text: HTML

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative condition that is characterized by motor symptoms as a result of dopaminergic degeneration, particularly in the mesostriatal pathway. However, in recent years, a greater number of clinical studies have focused on the emergence of non-motor symptoms in PD patients, as a consequence of damage on the mesolimbic and mesocortical dopaminergic networks, and on their significant impact on the quality of life of PD patients. Herein, we performed a thorough behavioral analysis including motor, emotional and cognitive dimensions, of the unilateral medial forebrain bundle (MFB) 6-hydroxidopamine (6-OHDA)-lesioned model of PD, and further addressed the impact of pharmacological interventions with levodopa and antidepressants on mood dimensions.Based on apomorphine-induced turning behaviour and degree of dopaminergic degeneration, animals submitted to MFB lesions were subdivided in complete and incomplete lesion groups. Importantly, this division also translated into a different severity of motor and exploratory impairments and depressive-like symptoms; in contrast, no deficits in anxiety-like and cognitive behaviors were found in MFB-lesioned animals. Subsequently, we found that the exploratory and the anhedonic behavioural alterations of MFB-lesioned rats can be partially improved with the administration of both levodopa or the antidepressant bupropion, but not paroxetine.Our results suggest that this model is a relevant tool to study the pathophysiology of motor and non-motor symptoms of PD. In addition, the present data shows that pharmacological interventions modulating dopaminergic transmission are also relevant to revert the non-motor behavioral deficits found in the disease.

Related Compounds

Structure Name/CAS No. Articles
Paroxetine maleate Structure Paroxetine maleate
CAS:64006-44-6
6-HYDROXYDOPAMINE HYDROBROMIDE Structure 6-HYDROXYDOPAMINE HYDROBROMIDE
CAS:636-00-0
Paroxetine hydrochloride hydrate Structure Paroxetine hydrochloride hydrate
CAS:110429-35-1
bupropion hydrochloride Structure bupropion hydrochloride
CAS:31677-93-7